QIAGEN N.V. announced a master collaboration agreement with Astellas Pharma Inc. to develop and commercialize companion diagnostics paired with Astellas drugs for use in cancer and other diseases. The scope of the agreement is not restricted to certain sample types, platforms, indications ... more
QIAGEN makes proposal to fully acquire Ipsogen
16-06-2011: QIAGEN N.V. has made an offer and entered into exclusive negotiations to purchase a 47% initial stake in Ipsogen S.A. and subsequently make a public offer to fully acquire a global leader in molecular profiling and personalized healthcare diagnostics for a broad range of hematological (blood) cancers.
The acquisition of Ipsogen, a publicly listed company founded in 1999 and based in Marseilles, France, would provide QIAGEN access to a broad range of assays covering 15 biomarkers used worldwide for the diagnosis, prognosis and monitoring of patients with various blood cancers. Many of these assays also are used as companion diagnostics in personalized healthcare to make and guide treatment decisions.
Almost all of Ipsogen’s assays have CE-IVD Marking in Europe and can be used on QIAGEN’s Rotor-Gene Q real-time PCR system, which will enable the smooth and rapid transfer of these unique products onto QIAGEN’s QIAsymphony RGQ, a novel integrated sample-to-result laboratory automation platform that includes the Rotor-Gene Q system.
“The acquisition of Ipsogen would further expand our global leadership in molecular assays for profiling and personalized healthcare,” said Peer Schatz, Chief Executive Officer of QIAGEN N.V. “Ipsogen’s molecular cancer profiling and personalized healthcare assays are clearly setting standards for the diagnosis and monitoring of many types of blood cancers as well as the selection and guidance of therapies. This portfolio would further increase our leading position in profiling assays, as well as in companion diagnostics for personalized healthcare, helping to improve the treatment of many diseases and addressing unmet medical needs.”
Ipsogen, which has approximately 70 employees at sites in France and the United States, reported 24% net sales growth in 2010 to €8.4 million (approximately $11 million) from a group of more than 400 active customers around the world. More than 40% of net sales were reinvested during 2010 into R&D activities.
All three managing cofounders – Vincent Fert (Chief Executive Officer), Stéphane Debono (Chief Operating Officer) and Fabienne Hermitte (R&D and Regulatory Affairs Senior Director) – are expected to stay with QIAGEN following the acquisition and contribute to the combined future mission.
QIAGEN N.V. announced it has acquired an exclusive global license to the biomarker SF3B1 from the University of Tokyo. SF3B1 is believed to play a critical role in the prognosis of patients with myelodysplastic syndromes (MDS), a group of hematological cancers in which bone marrow does not ... more
QIAGEN N.V. announced that it will expand access to its digene HPV Test across China through a co-marketing agreement with KingMed Diagnostics. Through the agreement, KingMed Diagnostics will function as a centralized lab, allowing smaller hospitals and those in less-populated areas to off ... more
QIAGEN N.V. has made an offer and entered into exclusive negotiations to purchase a 47% initial stake in Ipsogen S.A. and subsequently make a public offer to fully acquire a global leader in molecular profiling and personalized healthcare diagnostics for a broad range of hematological (blo ... more
- 1Schleicher & Schuell has been purchased by Whatman plc
- 2Thermo Fisher Scientific and Samsung Electronics to Collaborate on Point-of-Care Diagnostic Solutions
- 3QIAGEN makes proposal to fully acquire Ipsogen
- 4LGC rebrands reference standards
- 5Towards future lab-on-chip applications
- 6Failed Alzheimer’s test shows in which direction the research should continue
- 7Renishaw receives Queen's Award for spectroscopy developments
- 8The shadow of a disease
- 9Expansion of the WALDNER Group
- 10LIMS/LIS Market and POCT Supplement
- Prosensa Wins Scrip ‘Biotech Company of the Year’ 2014 Award
- GENALICE and deCODE Genetics enter into a partnership for population wide genomic analysis
- Spectris acquires Corporate Scientific Claisse Inc.
- Eurofins strengthens its European environmental testing market
- Development of multiplexing, disposable chips